牧山明資 (Akitaka Makiyama) - マイポータル

基本情報

所属: 岐阜大学医学部附属病院がんセンター准教授

学位: 医学博士(九州大学大学院)

ORCID ID: https://orcid.org/0000-0002-4017-668X
J-GLOBAL ID: 202001019659199288
Researcher ID: AAU-7256-2020
researchmap会員ID: R000000874

論文

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.

Daichi Watanabe, Hironori Fujii, Koichi Ohata, Hirotoshi Iihara, Akitaka Makiyama, Ryo Kobayashi, Chiemi Hirose, Shiori Hishida, Serika Matsuoka, Jesse Yu Tajima …

BMC cancer 23(1) 1078-1078 2023年11月8日
Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer.

Seiji Yamamoto, Hironori Fujii, Kotaro Murayama, Hirotoshi Iihara, Daichi Watanabe, Yunami Yamada, Ryo Kobayashi, Shigeru Kiyama, Akitaka Makiyama, Kimihiko Urano …

Anticancer research 43(11) 5099-5105 2023年11月
Late recurrent gastric carcinoma 12 years after surgery with attenuation of CD44 variant 9 expression.

Hirokatsu Hayashi, Itaru Yasufuku, Toshiya Higashi, Wakana Chikaishi, Ryoma Yokoi, Masahiro Fukada, Yuta Sato, Ryuichi Asai, Jesse Yu Tajima, Chiemi Saigo …

Surgical case reports 9(1) 87-87 2023年5月22日
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.

Serika Matsuoka, Hironori Fujii, Hirotoshi Iihara, Koichi Ohata, Chiemi Hirose, Daichi Watanabe, Shiori Sadaka, Shigeru Kiyama, Akitaka Makiyama, Takao Takahashi …

Anticancer research 43(5) 2351-2357 2023年5月
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa …

JAMA 329(15) 1271-1282 2023年4月18日
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Akitaka Makiyama, Masahito Kotaka, Hiroki Hara, Yoshinori Kagawa …

British Journal of Cancer 2023年3月4日
Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: a case report and literature review

Hirokatsu Hayashi, Akitaka Makiyama, Naoki Okumura, Itaru Yasufuku, Chiemi Saigo, Tamotsu Takeuchi, Tatsuhiko Miyazaki, Yoshihiro Tanaka, Nobuhisa Matsuhashi, Katsutoshi Murase …

BMC Gastroenterology 22(1) 2022年12月
Multicenter retrospective analysis of original versus modified FOLFIRINOX in metastatic pancreatic cancer: Results of the NAPOLEON study.

Junichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, Machiko Kawahira, Shiho Arima, Akio Ido, Futa Koga, Yujiro Ueda, Azusa Komori, Satoshi Otsu …

Oncology 101(1) 22-31 2022年10月4日
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site

Kazuo Nishikawa, Shuichi Hironaka, Takashi Inagaki, Azusa Komori, Satoshi Otsu, Kenji Mitsugi, Akitaka Makiyama, Koichiro Watanabe, Shingo Tamura, Yuta Okumura …

Japanese Journal of Clinical Oncology 52(12) 1416-1422 2022年9月1日
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer.

Hironori Fujii, Shiori Sadaka, Kanae Ajisawa, Naoki Okumura, Akitaka Makiyama, Hirotoshi Iihara, Itaru Yasufuku, Koichi Ohata, Ryo Kobayashi, Yoshihiro Tanaka …

Anticancer research 42(9) 4581-4588 2022年9月
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer

Hironaga Satake, Yoshinori Kagawa, Eiji Shinozaki, Yoshinori Tanizawa, Long Jin, Zhihong Cai, Akitaka Makiyama

ADVANCES IN THERAPY 39(6) 2596-2613 2022年6月
A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701

Kazuma Kobayshi, Koichi Suyama, Hiroo Katsuya, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka …

European Journal of Cancer 166 279-286 2022年5月
One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis.

Daichi Watanabe, Hirotoshi Iihara, Hironori Fujii, Akitaka Makiyama, Shohei Nishida, Akio Suzuki

The oncologist 2022年4月15日
Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy.

Hironori Fujii, Yukino Ueda, Chiemi Hirose, Koichi Ohata, Kumiko Sekiya, Mika Kitahora, Shiori Sadaka, Senri Yamamoto, Daichi Watanabe, Hiroko Kato-Hayashi …

Journal of pharmaceutical health care and sciences 8(1) 8-8 2022年3月2日
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).

Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori …

BMC cancer 22(1) 19-19 2022年1月3日
Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.

Masaaki Iwatsuki, Hiroyuki Orita, Kazuma Kobayashi, Shigekazu Hidaka, Takaaki Arigami, Tetsuya Kusumoto, Hironaga Satake, Eiji Oki, Satoshi Tsutsumi, Kazutoshi Tobimatsu …

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 25(1) 180-187 2022年1月
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, Seiichiro Mitani, Masato Komoda, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama …

BMC Cancer 21(1) 2021年12月
高齢者進行・再発胃癌に対するS-1+ラムシルマブ療法の多施設共同第II相試験(KSCC1701)

伊澤直樹, 陶山浩一, 勝屋弘雄, 小林和真, 上之園芳一, 胡慶江, 下川元継, 牧山明資, 佐伯浩司, 沖英次 …

日本癌治療学会学術集会抄録集 59回 O49-2 2021年10月
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)

Yoshikazu Takahashi, Yu Sunakawa, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yosuke Kito, Yusuke Akamaru, Masazumi Takahashi, Hiroshi Yabusaki, Jin Matsuyama …

Gastric Cancer 25(1) 235-244 2021年8月24日
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).

Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, Akio Ido, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Masaru Fukahori …

Pancreas 50(7) 957-964 2021年8月1日

もっとみる

MISC

高齢者進行・再発胃癌に対するS-1+ラムシルマブ療法の多施設共同第II相試験(KSCC1701)

伊澤直樹, 陶山浩一, 勝屋弘雄, 小林和真, 上之園芳一, 胡慶江, 下川元継, 牧山明資, 佐伯浩司, 沖英次 …

日本癌治療学会学術集会抄録集 59回 O49-2 2021年10月
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

Akihito Tsuji, Hisatsugu Ohori, Tatsuro Yamaguchi, Masato Matsuura, Atsujiro Nishioka, Akitaka Makiyama, Shingo Noura, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka …

JOURNAL OF CLINICAL ONCOLOGY 39(15) 2021年5月
A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

Hiroo Katsuya, Koichi Suyama, Kazuma Kobayashi, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka …

JOURNAL OF CLINICAL ONCOLOGY 39(15) 2021年5月
Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial

Naoki Izawa, Kohei Shitara, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama …

JOURNAL OF CLINICAL ONCOLOGY 38(4) 2020年2月
Final results of multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study)

Masato Nakamura, Hironaga Satake, Koji Oba, Masahito Kotaka, Yoshinori Kagawa, Hisateru Yasui, Takanori Watanabe, Toshihiko Matsumoto, Takayuki Kii, Tetsuji Terazawa …

JOURNAL OF CLINICAL ONCOLOGY 38(4) 2020年2月
Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).

Masahito Kotaka, Hironaga Satake, Koji Oba, Yoshinori Kagawa, Hisateru Yasui, Masato Nakamura, Takanori Watanabe, Toshihiko Matsumoto, Takayuki Kii, Tetsuji Terazawa …

JOURNAL OF CLINICAL ONCOLOGY 37(4) 2019年2月
トラスツズマブ不応HER2陽性進行・再発胃癌におけるHER2 status再評価(KSCC1604)

有上貴明, 佐伯浩司, 柏田知美, 牧山明資, 岩槻政晃, 成田有季哉, 佐竹悠良, 松田佳子, 園田英人, 下川元継 …

日本癌治療学会学術集会抄録集 56回 O58-6 2018年10月
Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.

Mototsugu Shimokawa, Eiji Oki, Takuhiro Yamaguchi, Hiroaki Tanioka, Yuji Miyamoto, Akihito Tsuji, Masako Asayama, Takeshi Shiraishi, Satoshi Yuki, Masahito Kotaka …

JOURNAL OF CLINICAL ONCOLOGY 36(15) 2018年5月
Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

Yasutaka Sukawa, Akitaka Makiyama, Taito Esaki, Gen Hirano, Masato Komoda, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Takashi Tsuda, Akihito Tsuji …

JOURNAL OF CLINICAL ONCOLOGY 36(15) 2018年5月
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.

Tomohiro Nishina, Hiroya Taniguchi, Daisuke Sakai, Hisato Kawakami, Naotoshi Sugimoto, Hiroki Hara, Taito Esaki, Tadamichi Denda, Akitaka Makiyama, Masahiro Tsuda …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).

Yoshiyuki Yamamoto, Wataru Okamoto, Akitaka Makiyama, Kohei Shitara, Tadamichi Denda, Takashi Ogura, Yasuyuki Nakano, Tomohiro Nishina, Masato Komoda, Hiroki Hara …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
70歳以上の結腸・直腸癌患者に対するTFTD(TAS-102)とBevacizumabの第II相臨床試験

沖英次, 佐伯浩司, 牧山明資, 中西良太, 掛地吉弘, 赤木由人, 馬場秀夫, 前原喜彦

日本癌治療学会学術集会抄録集 55回 SR-1 2017年10月
Approaches to cancer treatment in the elderly: Gastric cancer

Akitaka Makiyama

ANNALS OF ONCOLOGY 28 2017年10月
Dynamic changes in levels of gene mutations using circulating tumor DNA (ctDNA) and efficacy of 1st-line modified (m)-FOLFOXIRI plus bevacizumab (bev) for metastatic colorectal cancer (mCRC) harboring RAS mutation (mt) (JACCRO CC-11)

Y. Sunakawa, T. Sekikawa, J. Usher, H. Satake, Y. Jaimes, Y. Miyamoto, M. Nakamura, H. Nakayama, K. Kazama, A. Takagane …

ANNALS OF ONCOLOGY 28 2017年9月
Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)

S. Yuki, Y. Komatsu, H. Satake, Y. Miyamoto, H. Tanioka, A. Tsuji, M. Asayama, T. Shiraishi, M. Kotaka, A. Makiyama …

ANNALS OF ONCOLOGY 27 2016年10月
TGF-beta regulates CD44 expression of cancer cells through epithelial-to-mesenchymal transition in malignant ascites

Michitaka Nakano, Mamoru Tanaka, Risa Tanaka, Akitaka Makiyama, Keita Uchino, Taito Esaki, Kenji Mitsuki, Eishi Baba

ANNALS OF ONCOLOGY 27 2016年7月
Trifluridine-tipiracil for multidrug-resistant advanced colorectal cancer: A multicenter retrospective study

Shuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, Hozumi Kumagai, Gen Hirano, Akitaka Makiyama, Yoshihiro Shibata, Shingo Tamura, Hitoshi Kusaba, Eishi Baba

ANNALS OF ONCOLOGY 26 99-100 2015年11月
Multicenter retrospective analysis for elderly patients with advanced gastric cancer (AGC) received first-line chemotherapy in clinical practice.

Kenji Kunieda, Akitaka Makiyama, Masaaki Noguchi, Takeshi Kajiwara, Takao Tamura, Koji Takeda, Yasushi Tsuji, Keiko Minashi, Toshikazu Moriwaki, Naotoshi Sugimoto …

JOURNAL OF CLINICAL ONCOLOGY 33(15) 2015年5月
Exploratory analysis of a prognosis predictive formula for metastatic colorectal cancer treated with chemotherapy.

Mamoru Tanaka, Hitoshi Kusaba, Satomi Mukaide, Junji Kishimoto, Hozumi Kumagai, Akitaka Makiyama, Tsuyoshi Shirakawa, Hisanobu Oda, Masato Komoda, Kenji Mitsugi …

JOURNAL OF CLINICAL ONCOLOGY 33(3) 2015年1月
ANTI-EGFR ANTIBODY RECHALLENGE IN CHEMOREFRACTORY PATIENTS WITH METASTATIC COLORECTAL CANCER

Tatsuhiro Kajitani, Akitaka Makiyama, Shuji Arita, Hozumi Kumagai, Hisanobu Oda, Tsuyoshi Shirakawa, Taito Esaki

ANNALS OF ONCOLOGY 25 2014年10月

もっとみる

牧山明資

基本情報

論文

MISC

メニュー

共著者の一覧